

Explore Recent Scientific Contributions Using Invivoscribe's Products

Key opinion leaders across the world have recently published papers that discuss the advantages of using highly sensitive next-generation sequencing (NGS) for Minimal Residual Disease (MRD) testing.

Key Topics Discussed:

- » MRD testing for Multiple Myeloma, CLL & AML with NGS
- » Transitioning from Capillary Electrophoresis to NGS
- » Advantages of using NGS versus Flow Cytometry



Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

Ha, J et al. (2022) *The Journal of Molecular Diagnostics*. 24(1):48-56.

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Ho, C et al. (2021) *The Journal of Molecular Diagnostics*. 23(2):181-199.



NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter's Transformation and CLL/SLL

Kadkol, S S et al. (2021) *Case Reports in Hematology*. 2021:9740281.

Immunoglobulin Gene Rearrangement in Koreans with Multiple Myeloma: Clonality Assessment and Repertoire Analysis Using Next-Generation Sequencing

Kim, M et al. (2021) *PLoS One*. 16(6):e0253541.




Validation of a Next-Generation Sequencing-Based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

Ho, C C et al. (2021) *The Journal of Molecular Diagnostics*. 23(7):805-815.

Key Publications:

Simple Deep Sequencing–Based Post-Remission MRD Surveillance Predicts Clinical Relapse in B-ALL

Cheng, S et al. (2018) *Journal of Hematology & Oncology*. 11(1):105.



Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

Stamatopoulos, B et al. (2017) *Leukemia*. 31(4):837–845.

A Next-generation Sequencing–Based Assay for Minimal Residual Disease Assessment in AML: Patients with *FLT3*-ITD Mutations

Levis, M J et al. (2018) *Blood Advances*. 2(8):825–831.



Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

Arcila, M E et al. (2018) *The Journal of Molecular Diagnostics*. 21(2):330–342.

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Yao, Q et al. (2019) *Frontiers in Oncology*. 9:449.



None of the claims in the publications have been validated by Invivoscribe or reviewed by a regulatory authority.



PRODUCTS

Best-in-Class
Assays & Reagents



LABPMM®

Global Clinical
Lab Services

About Invivoscribe

If you are interested in more information on how to implement NGS LymphoTrack® Assays for clonality and MRD testing on the Illumina® or Thermo Fisher® platforms used in your laboratory, please contact

inquiry@invivoscribe.com



PARTNERSHIPS

Accelerate Drug
Approvals



BIOINFORMATICS

Software Licensing,
& Cloud Services



INTELLECTUAL

Property

 **invivoscribe®**

www.invivoscribe.com

San Diego,
California

Munich,
Germany

Kawasaki,
Japan

Shanghai,
China

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx